DNA methylation changes in epithelial ovarian cancer histotypes

被引:45
作者
Earp, Madalene A. [1 ]
Cunningham, Julie M. [2 ]
机构
[1] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
关键词
Ovarian cancer; Histotypes; Methylation; CLEAR-CELL CARCINOMA; GENE PROMOTER METHYLATION; ACQUIRED CISPLATIN RESISTANCE; PLATINUM-BASED CHEMOTHERAPY; PROGRESSION-FREE SURVIVAL; SEROUS BORDERLINE TUMORS; GENOME-WIDE ASSOCIATION; POOR-PROGNOSIS; SUSCEPTIBILITY LOCI; DRUG-RESISTANCE;
D O I
10.1016/j.ygeno.2015.09.001
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Survival after a diagnosis of ovarian cancer has not improved, and despite histological differences, treatment is similar for all cases. Understanding the molecular basis for ovarian cancer risk and prognosis is fundamental, and to this end much has been gleaned about genetic changes contributing to risk, and to a lesser extent, survival. There's considerable evidence for genetic differences between the four pathologically defined histological sub-types; however, the contribution of epigenetics is less well documented. In this report, we review alterations in DNA methylation in ovarian cancer, focusing on histological subtypes, and studies examining the roles of methylation in determining therapy response. As epigenetics is making its way into clinical care, we review the application of cell free DNA methylation to ovarian cancer diagnosis and care. Finally, we comment on recurrent limitations in the DNA methylation literature for ovarian cancer, which can and should be addressed to mature this field. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:311 / 321
页数:11
相关论文
共 161 条
[1]   LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients [J].
Akers, Stacey N. ;
Moysich, Kirsten ;
Zhang, Wa ;
Lai, Golda Collamat ;
Miller, Austin ;
Lele, Shashikant ;
Odunsi, Kunle ;
Karpf, Adam R. .
GYNECOLOGIC ONCOLOGY, 2014, 132 (02) :462-467
[2]   Circulating Tumor Cells and Circulating Tumor DNA [J].
Alix-Panabieres, Catherine ;
Schwarzenbach, Heidi ;
Pantel, Klaus .
ANNUAL REVIEW OF MEDICINE, VOL 63, 2012, 63 :199-215
[3]   BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].
Alsop, Kathryn ;
Fereday, Sian ;
Meldrum, Cliff ;
deFazio, Anna ;
Emmanuel, Catherine ;
George, Joshy ;
Dobrovic, Alexander ;
Birrer, Michael J. ;
Webb, Penelope M. ;
Stewart, Colin ;
Friedlander, Michael ;
Fox, Stephen ;
Bowtell, David ;
Mitchell, Gillian .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663
[4]  
[Anonymous], P 2015 ANN M AM ASS
[5]  
Anthoney DA, 1996, CANCER RES, V56, P1374
[6]   Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas [J].
Arai, Eri ;
Chiku, Suenori ;
Mori, Taisuke ;
Gotoh, Masahiro ;
Nakagawa, Tohru ;
Fujimoto, Hiroyuki ;
Kanai, Yae .
CARCINOGENESIS, 2012, 33 (08) :1487-1493
[7]   Epigenetics of ovarian cancer: From the lab to the clinic [J].
Asadollahi, Reza ;
Hyde, Caroline A. C. ;
Zhong, Xiao Yan .
GYNECOLOGIC ONCOLOGY, 2010, 118 (01) :81-87
[8]   Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].
Audeh, M. William ;
Carmichael, James ;
Penson, Richard T. ;
Friedlander, Michael ;
Powell, Bethan ;
Bell-McGuinn, Katherine M. ;
Scott, Clare ;
Weitzel, Jeffrey N. ;
Oaknin, Ana ;
Loman, Niklas ;
Lu, Karen ;
Schmutzler, Rita K. ;
Matulonis, Ursula ;
Wickens, Mark ;
Tutt, Andrew .
LANCET, 2010, 376 (9737) :245-251
[9]   Epigenetic Changes in Ovarian Cancer [J].
Balch, Curt ;
Fang, Fang ;
Matei, Daniela E. ;
Huang, Tim H. -M. ;
Nephew, Kenneth P. .
ENDOCRINOLOGY, 2009, 150 (09) :4003-4011
[10]  
Baldwin RL, 2000, CANCER RES, V60, P5329